Literature DB >> 25758238

[Study and therapy of metastatic castration-resistant prostate cancer: A randomized, double blind, multicenter, parallel-group, phase III study to evaluate efficacy and safety of DCVAC/PCa versus placebo in men with metastatic castration resistant prostate cancer eligible for first line chemotherapy (VIABLE) - AUO study AP 78/13].

H Rexer1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25758238     DOI: 10.1007/s00120-015-3801-8

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  2 in total

Review 1.  Trial watch: Dendritic cell-based anticancer immunotherapy.

Authors:  Abhishek D Garg; Monica Vara Perez; Marco Schaaf; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-05-12       Impact factor: 8.110

Review 2.  Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions.

Authors:  Gina M Graziani; Jonathan B Angel
Journal:  J Int AIDS Soc       Date:  2015-11-09       Impact factor: 5.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.